Scarica l'app Stockscreener
63.39
0.25%
0.16
Dopo l'orario di chiusura:
63.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca PLC Borsa (AZN) Ultime notizie
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLCAZN - PR Newswire
Stocks in news: Waaree Energies, GMR Infra, AstraZeneca, Indus Towers, Ashoka Buildcon & ITI - Business Today
AstraZeneca Tries Plan B For Dato-DXd After Regulator Feedback - Citeline
AstraZeneca PLC ADR rises Monday, still underperforms market - MarketWatch
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership - Pharmaceutical Technology
Is AstraZeneca PLC (AZN) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
Is AstraZeneca PLC (AZN) A Cheap NASDAQ Stock To Invest In Now? - Insider Monkey
AstraZeneca's Tagrisso recommended for EU approval - ShareCast
AstraZeneca: new positive CHMP opinion for Tagrisso - Marketscreener.com
AstraZeneca's cell lung cancer drug sent for EU approval - baha news
Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca - Korea Economic Daily
Natixis Advisors LLC Boosts Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Sees Large Increase in Short Interest - MarketBeat
AstraZeneca PLC (LON:AZN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
FIVE at FIVE: GSK, AstraZeneca plummet; LandSec profits; Economy stalls; FTSE 100 meanders; TT snubs Volex - Proactive Investors USA
AstraZeneca PLC (LON:AZN) Insider Pascal Soriot Purchases 20,000 Shares - MarketBeat
Trump anti-vax health appointment wipes £7bn from AstraZeneca and GSK - Proactive Investors USA
FTSE 100 Live: Index regains; GSK, AstraZeneca weighUK economic growth slows - Proactive Investors UK
AstraZeneca rises Thursday, outperforms market - MarketWatch
July 2025 Options Now Available For AstraZeneca (AZN) - Nasdaq
Is AstraZeneca a Buy as It Eyes the Weight Loss Market? - The Motley Fool
AstraZeneca talks up US growth as China problems fester - The Boston Globe
AstraZeneca Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
China has trapped the tiger of AstraZeneca’s growth - Financial Times
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity (NASDAQ:AZN) - Seeking Alpha
AstraZeneca PLC ADR rises Wednesday, outperforms market - MarketWatch
AstraZeneca pledges $3.5bn to biopharma research and manufacturing - BioProcess Insider
AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Call Transcript - MSN
AstraZeneca: Stifel confirms its 'buy' rating on the stock - Marketscreener.com
MQS Management LLC Has $832,000 Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial - Yahoo Finance
AstraZeneca plans major $3.5bn expansion drive in the US - Investment Monitor
MSD and AstraZeneca report positive topline data from Koselugo trial for NF1 - Clinical Trials Arena
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong R - GuruFocus.com
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcript - The Motley Fool
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US - Yahoo Finance
Trending : AstraZeneca Expands Its Investment Plan in the U.S. - Marketscreener.com
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously' - AOL
AstraZeneca, Daiichi file for FDA accelerated approval of Dato-DXd (NASDAQ:AZN) - Seeking Alpha
AstraZeneca lifts 2024 outlook, doubles down on US plans - Yahoo Finance UK
AstraZeneca rises Tuesday, outperforms market - MarketWatch
AstraZeneca Talks Up US Growth as China Problems Fester - Bloomberg
AstraZeneca says detained China head has lawyer, but company still in dark - Yahoo Finance UK
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales - BioSpace
ASTRAZENECA : Q3 beat + guidance upgrade weigh lighter than the Chinese uncertainty - Marketscreener.com
Exclusive | AstraZeneca Expands U.S. Investment Plan - The Wall Street Journal
Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial - Marketscreener.com
AstraZeneca to spend $3.5B to expand U.S. operations (NASDAQ:AZN) - Seeking Alpha
AstraZeneca Talks Up US Growth as China Problems Worsen - MSN
AstraZeneca: 450 million pound investment in UK under review amid talks with govt - Reuters.com
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q3 Earnings - Yahoo Finance
AstraZeneca boss says China arrests taken ‘very seriously’ - Proactive Investors USA
AstraZeneca: 450 million pound investment in UK on hold amid talks with govt - Marketscreener.com
Here's Why AstraZeneca (LON:AZN) Has Caught The Eye Of Investors - Yahoo Finance UK
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):